Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium
Authors:
- Matthew D. LeeMLMatthew D. Lee
- Sohil H. PatelSPSohil H. Patel
- Suyash MohanSMSuyash Mohan
- Hamed AkbariHAHamed Akbari
- Spyridon BakasSpyridon Bakas
- MacLean P. NasrallahMNMacLean P. Nasrallah
- Evan CalabreseECEvan Calabrese
- Jeffrey RudieJRJeffrey Rudie
- Javier Villanueva-MeyerJVJavier Villanueva-Meyer
- Pamela LaMontagnePLPamela LaMontagne
- Daniel S. MarcusDMDaniel S. Marcus
- Rivka R. ColenRCRivka R. Colen
- 19 July 2023
- journal article
- research article
- Published by Springer Nature in Neuroradiology
- Vol. 65 (9) , 1343-1352
Abstract
Purpose While the T2-FLAIR mismatch sign is highly specific for isocitrate dehydrogenase (IDH)-mutant, 1p/19q-noncodeleted astrocytomas among lower-grade gliomas, its utility in WHO grade 4 gliomas is not well-studied. We derived the partial T2-FLAIR mismatch sign as an imaging biomarker for IDH mutation in WHO grade 4 gliomas. Methods Preoperative MRI scans of adult WHO grade 4 glioma patients (n = 2165) from the multi-institutional ReSPOND (Radiomics Signatures for PrecisiON Diagnostics) consortium were analyzed. Diagnostic performance of the partial T2-FLAIR mismatch sign was evaluated. Subset analyses were performed to assess associations of imaging markers with overall survival (OS). Results One hundred twenty-one (5.6%) of 2165 grade 4 gliomas were IDH-mutant. Partial T2-FLAIR mismatch was present in 40 (1.8%) cases, 32 of which were IDH-mutant, yielding 26.4% sensitivity, 99.6% specificity, 80.0% positive predictive value, and 95.8% negative predictive value. Multivariate logistic regression demonstrated IDH mutation was significantly associated with partial T2-FLAIR mismatch (odds ratio [OR] 5.715, 95% CI [1.896, 17.221], p = 0.002), younger age (OR 0.911 [0.895, 0.927], p < 0.001), tumor centered in frontal lobe (OR 3.842, [2.361, 6.251], p < 0.001), absence of multicentricity (OR 0.173, [0.049, 0.612], p = 0.007), and presence of cystic (OR 6.596, [3.023, 14.391], p < 0.001) or non-enhancing solid components (OR 6.069, [3.371, 10.928], p < 0.001). Multivariate Cox analysis demonstrated cystic components (p = 0.024) and non-enhancing solid components (p = 0.003) were associated with longer OS, while older age (p < 0.001), frontal lobe center (p = 0.008), multifocality (p < 0.001), and multicentricity (p < 0.001) were associated with shorter OS. Conclusion Partial T2-FLAIR mismatch sign is highly specific for IDH mutation in WHO grade 4 gliomas.Keywords
Funding Information
- National Cancer Institute (R01CA269948)
This publication has 28 references indexed in Scilit:
- The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation studyNeuro-Oncology, 2018
- Residual Convolutional Neural Network for the Determination of IDH Status in Low- and High-Grade Gliomas from MR ImagingClinical Cancer Research, 2018
- T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA ProjectClinical Cancer Research, 2017
- Incidence and prognostic significance of non‐enhancing cortical signal abnormality in glioblastomaJournal of Medical Imaging and Radiation Oncology, 2015
- The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS)IEEE Transactions on Medical Imaging, 2015
- IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resectionNeuro-Oncology, 2013
- Relationship between Tumor Enhancement, Edema,IDH1Mutational Status,MGMTPromoter Methylation, and Survival in GlioblastomaAmerican Journal of Neuroradiology, 2012
- The SRI24 multichannel atlas of normal adult human brain structureHuman Brain Mapping, 2009
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008
- MR Imaging Correlates of Survival in Patients with High-Grade Gliomas2005